Search

Biology of Aging Seminar
academic-centers › ... › biology-of-aging-seminar
… Room 201A  Faculty Group Seminar: Ergun Sahin   March 26 Cullen Room 201A Kevin F. Bieniek, Ph.D. Associate …
Space health institute seeks proposals to counteract spaceflight body wear-and-tear
news › space-health-institute-seeks-proposals-to-counteract-spaceflight-body-wear-and-tear
… is composed of two phases. Step-1 proposals are due Jan. 26, 2022, by 5 p.m. EST. Step-2 proposals from selected …
FDA Grants Orphan Drug Designation to Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy
news › fda-grants-orphan-drug-designation-to-potential-treatment-of-stxbp1-developmental-and-epileptic-encephalopathy
… by STXBP1 mutations is estimated to affect up to one in 26,000 children globally. It is associated with …
Transportation, Parking and Hotel Information
education › ... › transportation-parking-and-hotel-information
… convenient to interview session activities we recommend visiting hotels.com . Use zip code 77030 to perform a search. … The latest travel advisory and traffic information can be found …
Beeton Lab News
research › ... › news
… Members of the Beeton Lab spoke with Emily Akin from Fox 26 Houston News about our work with Dalazatide (ShK-186) for …
HER2CLIMB-02: Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Patients with HER2-positive Breast Cancer (H-46822)
healthcare › clinical-trials › h-46822
… + T-DM1. Both tucatinib and T-DM1 are approved by the FDA for the treatment of breast cancer. … HER2CLIMB-02: Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Patients with HER2-positive Breast Cancer …
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd Salvage (D18-11141) (H-45373)
healthcare › clinical-trials › h-45373
… depending on the patient's prior induction treatment.   For more information: https://clinicaltrials.gov/ct2/show/NCT03926624 . … Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd Salvage (D18-11141) …
S2207: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment (H-54903)
healthcare › clinical-trials › h-54903
… effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell … or extend the time without cancer symptoms coming back. For more information: …
Division of Pediatric Tropical Medicine
departments › ... › tropical-medicine
… of Tropical Medicine and the Division of Tropical Medicine. Visit the NSTM public policy page for information. …
Pediatric Hospital Medicine Fellowship Admissions and Benefits
departments › ... › admissions-and-benefits
… PHM Fellow Application which can be found through the ERAS website starting early July. Interviews are typically … Matching Program in December. For more information, visit the official Match website . Direct questions to sxolney@texaschildrens.org . … on ERAS For more information, please visit the ERAS website . We are committed to holistically reviewing every …